step 1 trial semaglutide 2.4 mg weight loss nejm 2021 Once-weekly 7·2 in adults with obesity (STEP UP): a randomised, controlled, phase 3b Comparing GLP-type therapies for weight

The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health

Comparative Receptor Mechanisms and Efficacy Expectations Tirzepatide activates both GIP and GLP-1 receptors, producing synergistic glucose control and robust weight loss averaging 20-22% at maximum dose in clinical trials

Aspens entry could pressure Novo Nordisk to adjust its pricing or ramp up supply to maintain market share

Retatrutides relevance here is that improved glucose handling was one of its most consistent trial findings

Benefit-risk assessment of exenatide in the therapy of type 2 diabetes mellitus

34.4% of adherent participants achieved at least 20% weight loss